Compare

Two terms, side by side

Pick any two terms to see definitions, context, pitfalls, and sources in parallel.

Reimbursement

Budget Impact Model(BIM)

In one line

Financial model that estimates the total cost consequences of adopting a new technology to a payer's budget over a defined horizon.

Definition

A Budget Impact Model (BIM) projects the financial impact to a specific payer (commercial plan, Medicare, integrated health system) of adopting a new technology, typically over 3-5 years, accounting for population size, uptake curve, acquisition cost, offset costs (avoided procedures, hospitalizations, complications), and net budget effect. BIM complements cost-effectiveness analysis but answers a different question: 'Can the payer afford it?' rather than 'Is it good value per QALY?'

Why it matters

Most US payer access decisions are influenced more by BIM than by cost-effectiveness analysis, because US payers typically don't apply a formal QALY threshold. A clean, defensible BIM with conservative offset assumptions is often the deciding artifact.

Common pitfalls

•Overstating offset savings (avoided procedures) — payers discount aggressive assumptions heavily.
•Modeling national populations when the payer cares only about its own enrolled population.

Sources

ISPOR Budget Impact Analysis Good Practices II · ISPOR
AMCP Format for Formulary Submissions · AMCP
AMA CPT Resources · AMA

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.